Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy

• Monica Galli,
• Manik Chatterjee,
• Mariella Grasso,
• Giorgina Specchia,
• Hila Magen,
• Hermann Einsele,
• Ivana Celeghini,
• Paola Barbieri,
• David Paoletti,
• Silvia Pace,
• Ralph D. Sanderson,
• Alessandro Rambaldi,
• Arnon Nagler

Affiliations

Monica Galli

Hematology and Bone Marrow Transplant Unit, ASST- Papa Giovanni XXIII, Bergamo, Italy

Manik Chatterjee

Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Germany

Mariella Grasso

S.C Ematologia, ASO S.Croce e Carle, Cuneo, Italy

Giorgina Specchia

U.O Complessa di Ematologia con Trapianto, A.O. Universitaria Policlinico Consorziale di Bari, Italy

Hila Magen

Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel

Hermann Einsele

Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Germany

Ivana Celeghini

S.C Ematologia, ASO S.Croce e Carle, Cuneo, Italy

Paola Barbieri

Leadiant Biosciences SA, Mendrisio, Switzerland

David Paoletti

Leadiant Biosciences SA, Mendrisio, Switzerland

Silvia Pace

Alfasigma SpA, Pomezia (Rome), Italy

Ralph D. Sanderson

University of Alabama at Birmingham, AL, USA

Alessandro Rambaldi

Hematology and Bone Marrow Transplant Unit, ASST- Papa Giovanni XXIII, Bergamo, Italy;Department of Oncology and Hematology-Oncology, University of Milan, Italy

Arnon Nagler

Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel